This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"

Advantages and Disadvantages of Different Treatment Methods in Achondroplasia

2022-05-12Research
This recent article presents the current and potential pharmacological treatments for achondroplasia, highlighting the advantages and disadvantages of all the drugs that have been demonstrated in human and animal studies in different stages of clinical trials.

The European Achondroplasia Forum

2022-03-09Research
The EAF is a network of specialists in achondroplasia management representative of the achondroplasia clinical community...

Hearing loss in adults with achondroplasia

2021-11-30Research
A recent study (published in November 2021 in the Orphanet Journal of Rare Diseases) investigates the prevalence, severity and type of hearing loss in Norwegian adults with achondroplasia. Recurrent otitis media infections, chronic middle ear effusion, and hearing loss are common in children with achondroplasia (about 70%) yet few studies have investigated hearing loss in adults with this condition.

CLARITY - a Natural History Study of Achondroplasia in the US

2021-10-19Research
The risk of adverse health outcomes in achondroplasia, from cardiovascular diseases, pain, poor function, excess weight, and sleep apnea is unclear. This multicenter retrospective natural history study works as a patient registry and was conducted in the US to understand medical and surgical practices in achondroplasia.

Vosoritide for Achondroplasia - Another step towards commercialisation in the EU

2021-07-31Research
On June 25, 2021, the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency, EMA, recommended the marketing authorisation of Voxzogo (trade name of vosoritide) in the European Union (EU)...

The Pros and Cons in each different treatment for Achondroplasia

2021-07-14Research
This recent study by Dr. Wiktoria Wrobel (Medical University of Lublin, Poland) brings together the different pharmacological treatments for achondroplasia, both current and potential, highlighting the advantages and disadvantages of each, making it a great comprehensive review.
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.


Thank You.